Omzo vs Pallas Health: Compounded GLP-1 Plans Compared
Quick verdict: Both provide clinician-reviewed GLP-1 plans, but Omzo centers on personalized compounded semaglutide and tirzepatide starting at $179 while Pallas Health offers clinician-selected brand-name or compounded options with compounded semaglutide from $139 first month. Choose based on whether you want an all-in plan that includes provider care and an option to receive FDA-approved brands.
Explore Omzo’s clinician-guided plans
Omzo vs Pallas Health: pricing and plan structure
Pricing is a major difference. Omzo lists compounded semaglutide starting at $179 and tirzepatide starting at $279, with medication costs included in fees collected by Omzo. Pallas Health advertises compounded semaglutide at $139 for the first month, then $597 every 12 weeks (about $199/mo average), and compounded tirzepatide $179 first month then $897 every 12 weeks (about $299/mo average). Pallas also publishes cash-pay brand‑name monthly prices for Wegovy, Ozempic, Zepbound and Mounjaro.
What the prices mean for you
Omzo presents starting prices for compounded options and notes medication costs are included in its fees. Pallas emphasizes an intro month price then 12-week renewal pricing for compounded plans and shows brand-name cash-pay figures. Confirm current figures at checkout with either provider.
Primary differences in medication options and regulatory notes
Both providers offer compounded GLP-1s but handle brand-name drugs differently. Omzo connects patients with licensed providers who may prescribe compounded medications or write prescriptions for branded FDA-approved medications; Omzo does not sell or ship branded medications. Pallas Health offers both FDA-approved brand-name GLP-1s and clinician-personalized compounded semaglutide or tirzepatide from intake.
Regulatory note: Both sources state that compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness or quality.
Care model, clinician review and included services
Omzo: Clinical services are provided by third party networks of U.S.-licensed clinicians who determine eligibility and make prescribing decisions. Omzo is not a medical practice and says the online assessment does not create a doctor-patient relationship. Pallas Health: A U.S.-licensed clinician reviews your history and personalizes the plan; Pallas frames provider care, check-ins and messaging as included in one all-in plan price with no membership fee and offers asynchronous care in most states.
Compare Omzo clinician review process
Shipping, renewal cadence and logistics
Omzo notes fast, discreet delivery and FSA/HSA eligibility as described on its landing content, and that medication programs use state-licensed sterile compounding pharmacies. Pallas Health advertises free expedited, discreet shipping from U.S. compounding pharmacies and clarifies compounded plans renew every 12 weeks for the stated renewal prices.
Comparison table: key criteria
| Criteria | Omzo | Pallas Health |
|---|---|---|
| Starting compounded semaglutide price | $179 | $139 first month (then $199/mo avg) |
| Tirzepatide starting price | $279 | $179 first month (then $299/mo avg) |
| Brand-name GLP-1 availability | Providers may write prescriptions for branded medications; Omzo does not sell or ship branded meds | Offers FDA-approved Wegovy, Ozempic, Zepbound and Mounjaro as clinic options |
| Care model included | Clinician-guided plans reviewed by licensed U.S. providers; services delivered by third party clinician networks | One all-in plan price with clinician care, check-ins and messaging included; no membership fee |
| Shipping | Fast, discreet delivery noted | Free expedited, discreet shipping from U.S. compounding pharmacies |
| Regulatory note | Compounded medications are not FDA-approved | Compounded medications are not FDA-approved |
Other practical considerations
Pallas highlights that compounded plans are priced by medication rather than by milligram so titration does not raise the plan price, that it is cash-pay only and that a video visit is required in seven states plus Washington, D.C. Omzo emphasizes that providers make final prescribing determinations, that compounded medications supplied through its program are prepared by state-licensed sterile compounding pharmacies and that these compounded drugs are not FDA-approved.
Conclusion: Omzo vs Pallas Health
Omzo and Pallas Health both provide clinician-reviewed access to compounded GLP-1s, but Pallas builds brand-name and compounded options into a single intake with an all-in plan price and explicit first-month intro pricing. Omzo positions itself on personalized clinician-guided compounded programs with stated starting prices and notes that providers may instead prescribe brand-name products that patients fill elsewhere. Choose based on whether you prefer an all-in plan that includes provider care plus brand-name access or a platform focused on clinician-guided compounded offerings.
Choose Omzo if…
you want clinician-guided, personalized compounded semaglutide or tirzepatide programs with medication costs included in collected fees and you are comfortable confirming eligibility, total cost, renewal terms and state availability before enrollment.
Choose Pallas Health if…
you want a single intake where a clinician can pick FDA-approved brand-name GLP-1s or a compounded preparation, prefer an all-in plan price that includes provider care and check-ins, and value the published first-month compounded pricing with 12-week renewals.
Ready to Compare Telehealth Providers?
Explore leading providers — physician-supervised, all-inclusive pricing, and free home delivery.
Compare All Providers →More comparisons
